Foresee Pharmaceuticals Announces Completion of Last Patient Visit in Registration Phase 3 Study of LMIS 25 mg (fp-001) for the Treatment of Advanced Prostate Cancer
TAIPEI, , Nov. 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) today announced that all patients had completed participation in its Phase 3, multinational, multicenter trial of FP-001/LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg, a three-month, ready-to-use subcuta...
2018-11-26 21:30
1138
Foresee Pharmaceuticals Announces Results from Phase 1 Clinical Studies
TAIPEI, , Dec. 4, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today that it has successfully completed Phase 1 single and multiple ascending dose (SAD/MAD) clinical studies with FP-025, its novel, highly selective, oral small-molecule matrix metallopr...
2017-12-04 23:06
1223
